Interest in transfusion-associated Cytomegalovirus (CMV) infections began with the recognition that the overwhelming majority of cases of late-onset postperfusion mononucleosis were heterophile negative (1, 2) . In 1965 Klemola and Kaariainen (3) associated heterophile-negative mononucleosis with CMV infection, and 1 year later the same group documented the association of CMV infection with heterophile-negative posttransfusion mononucleosis (4) . Those patients experiencing CMV infection had not undergone extracorporeal perfusion but had been transfused with large volumes of fresh blood, which implied that asymptomatic carriage of CMV might be quite common. This supposition seemed to be borne out by Diosi et al. (5) in work published in 1968 which reported CMV isolation from the peripheral leukocytes of 2 out of 35 healthy blood donors. Since that time peripheral leukocytes from over 1500 blood donors have been inoculated into cell culture for virus isolation, but no CMV has been recovered. This work has been done in various parts of the world including Bristol, England (6), Pittsburgh (7), Cleveland (8) , Atlanta (9), Houston (10), Kansas City (1 1), and Seattle (12) .
Prospective studies have examined the incidence of CMV infection by serology in patients receiving multiple blood transfusions. Table 1 , taken from Randall and Plotkin (13) , lists these studies which have shown posttransfusion infection frequencies ranging from 21 to 38%. It is noteworthy that 10 to 15% of those infected developed the postperfusion syndrome. At this point it is important to emphasize the difference between infection and disease. "Disease" is a very simple English word that means just what it says.... dis -ease, or loss of comfort. "Infection", on the other hand, means the establishment of a host-parasite interaction and need not lead to damage to the host. There are many ways of detecting this interaction, ranging from isolation of the agent to evidence of the immunological response in the host. This table shows evidence of infection. Table 2 is taken from a paper by Krech (18) and shows the distribution of CMV complement Fixing (CF) antibodies in healthy blood donors in different parts of the world. Antibody prevalences range from 40% in highly industrialized areas to 100% in developing countries. It is interesting that antibody prevalences in Japan and Hong Kong are in excess of 90%, even though they cannot be considered developing areas. Table 3 is a summary of CMV CF antibody prevalence studies in blood donors living in Europe, Australia, and North America. The low prevalence reported in the study of Monif et al. (24) can be explained by the fact that the majority of the donors in Gainesville are college students, thus young and likely to be middle class. Additional studies reporting low antibody prevalences are those of Jack and McAuliffe directly onto Wentworth's human fetal tonsil fibroblasts. Seven donors (3%) were cytomegaloviruric, and Table 4 summarizes the laboratory data on these donors. Follow-up blood and urine cultures were taken from six of the seven cytomegaloviruric donors at times ranging from 6 to 14 weeks after donation; none of the cultures was positive for CMV. All viruric donors were antibody positive by CF and indirect hemagglutination (IHA) and their titers remained unchanged in those who were followed after donation. Their titers did not differentiate them from the nonviruric donors. Table 5 shows that 58% of all the donors had CMV CF titers of 1:8 or greater, while Table 6 documents that 59% of this group had IHA antibody titers of 1:10 or greater. When the CF and IHA titers from each donor were compared, the direct correlation illustrated in Table 7 was found. Six of the seven units taken from viruric donors were transfused, but only three of the six recipients lived long enough to be followed for evidence of CMV infection. The observation of CMV infection in three recipients of blood from cytomegaloviruric donors prompted us to continue our search for viruric donors in order to see if viruria rather than viremia might be a more reliable indicator of ability to transmit CMV infection via blood. We have followed an additional 420 donors for evidence of CMV infection by urine culture and serology. Only four donors (1%) were excreting CMV in their urine at the time of donation. Antibody prevalence to CMV by CF and IHA was 65% in this cohort. Two of the four units from viruric donors were transfused to patients who could be followed, and the recipients had pre-existing CMV CF antibody titers of 1:8 and 1:16, respectively. Neither recipient showed evidence of infection by virus isolation from the urine or by fourfold or greater rise in antibody titer. Thus, three of five recipients of blood from viruric donors have shown evidence of CMV infection subsequent to transfusion. This study is still in progress and will continue until larger numbers of recipients have been studied. We are also following recipients of blood from nonviruric donors who are matched by age, sex, hospital, and medical history to the patients receiving blood from cytomegaloviruric donors.
The large number of studies cited previously (6-1 1) which have unsuccessfully attempted to isolate CMV from the leukocytes of normal donors stands in sharp tributable to CMV were seen in any of the three patients experiencing CMV infection.
Our second study of open-heart patients, still in progress at Hospital B, has the same design as the one previously described. Table 10 displays the preliminary results of this study. Twenty patients have been followed, and none has shown evidence of CMV infection. An average of 2.5 units of blood was used for each case.
To evaluate the relative risk of CMV infection after transfusion with antibodypositive and antibody-negative blood, we have been studying the recipients of one and two unit transfusions (where both donors are either antibody positive or antibody negative). The data accumulated to date are presented in Table 11 . The number of patients followed is small, and therefore no conclusions can be drawn. Only 1 of 32 recipients has shown evidence of CMV infection. The patient, who had a presurgical CMV CF titer of 64, received two CMV antibody-positive units during hysterectomy and showed a fourfold rise and viruria at 12 weeks follow-up. No disease was seen in this patient.
In summary, transfusion-associated cytomegalovirus disease is not an obvious problem in this community, at least in terms of adult transfusions. Two factors which are responsible for the apparent absence of disease and the low frequency of CMV infections are excellent surgeons who use very little blood in their operative procedures and the high quality of the blood donor base in the Kansas City metropolitan area. CCMV was isolated from the recipient's urine at 8 weeks follow-up.
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